Sheng, Z., Song, S., Yu, M., Zhu, H., Gao, A., Gao, W., . . . Huo, D. (2020). Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: A network meta-analysis. Leukemia & lymphoma, 61(14), 3432-3439. https://doi.org/10.1080/10428194.2020.1811271
Chicago-Zitierstil (17. Ausg.)Sheng, Zhixin, Shilei Song, Miao Yu, Hongguang Zhu, Anran Gao, Weijie Gao, Xuehong Ran, und Da Huo. "Comparison of Acalabrutinib Plus Obinutuzumab, Ibrutinib Plus Obinutuzumab and Venetoclax Plus Obinutuzumab for Untreated CLL: A Network Meta-analysis." Leukemia & Lymphoma 61, no. 14 (2020): 3432-3439. https://doi.org/10.1080/10428194.2020.1811271.
MLA-Zitierstil (9. Ausg.)Sheng, Zhixin, et al. "Comparison of Acalabrutinib Plus Obinutuzumab, Ibrutinib Plus Obinutuzumab and Venetoclax Plus Obinutuzumab for Untreated CLL: A Network Meta-analysis." Leukemia & Lymphoma, vol. 61, no. 14, 2020, pp. 3432-3439, https://doi.org/10.1080/10428194.2020.1811271.